Journal of Clinical Oncology
Articles in this Issue
Sociodemographic factors and delays in care for gestational trophoblastic neoplasia.
e17617 Background: Delays in care are associated with worse outcomes for patients with the most common gynecologic cancers...
Lattice SFRT combined with systemic therapy for bulky unresectable hepatocellular carcinoma: A retrospective study on safety and efficacy.
e16270 Background: Lattice spatially fractionated radiotherapy (Lattice SFRT) creates highly heterogeneous “peak-and-valle...
Implementation and longitudinal capture of routine patient-reported outcomes in non–small cell lung cancer care at a JCI-certified center in Colombia (2022–2025).
e20105 Background: Routine patient-reported outcomes (PROs) support symptom monitoring and quality benchmarking, yet imple...
Racial disparities in endometrial cancer (EC) survival after molecular classification (MC).
5620 Background: Black (BAA) patients with EC have double the mortality rate compared to White patients. It is unclear if...
Monalizumab plus durvalumab plus platinum-based chemotherapy for first-line treatment of extensive stage small-cell lung cancer: Early efficacy results from MOZART trial.
8098 Background: Extensive stage small cell lung cancer (ES-SCLC) is an area of unmet need where novel treatment strategie...
Prognostic significance of muscle quantity and quality for overall survival in non-metastatic castration-resistant prostate cancer.
e17047 Background: This study evaluated whether computed tomography–derived skeletal muscle quantity and quality are assoc...
Use of LIF and LIFR expression to characterize survival and tumor microenvironment composition in lung adenocarcinoma.
8553 Background: In lung adenocarcinoma (LUAD), EGFR-directed therapy has transformed clinical practice, yet heterogeneity...
Tumor immune microenvironment of metastatic HR+ HER2- breast cancer treated with CDK4/6 inhibitors.
e13059 Background: Adding a CDK4/6 inhibitor (CDKi) to endocrine therapy has meaningfully improves outcomes for patients w...
Essential but unaffordable: Real-world costs of WHO essential cancer medicines in a low-income setting.
1508 Background: The World Health Organization (WHO) Essential Medicines List (EML) defines priority anticancer medicines....
The use of multimodal machine learning models for predicting overall survival in patients with non-small cell lung cancer: A systematic review.
e20000 Background: Multimodal machine-learning (ML) models that fuse imaging, pathology, omics, and clinical data...
Single cell spatial profiling for identification of organ-specific immune features in the peritumoral microenvironment of triple-negative breast cancer with liver metastases.
1126 Background: Breast cancer liver metastasis (BCLM) is associated with poor prognosis. Prior studies have described liv...
Butaselen combined with radiotherapy for newly diagnosed H3K27M-mutant spinal diffuse midline glioma: A single-arm phase Ib trial.
2014 Background: Patients with H3K27M-mutant spinal diffuse midline glioma (sDMG) have a median overall survival (OS) of a...
Cost-effectiveness analysis of eight treatments for metastatic hormone-sensitive prostate cancer (mHSPC) stratified by homologous recombination repair (HRR) status.
e17060 Background: After approval of androgen deprivation therapy (ADT) with niraparib and abiraterone/prednisone (NAAP) f...
Earlier CRS identification with continuous wearable monitoring in outpatient CAR T-cell therapy.
1633 Background: CAR-T cell therapy has transformed outcomes of hematologic malignancies and is poised to expand into soli...
Safety and survival outcomes of immune checkpoint inhibitors in metastatic lung cancer patients with pre-existing autoimmune disease: A propensity-matched real-world analysis.
e20615 Background: Patients with cancer and pre-existing autoimmune diseases (AID) are frequently excluded from immune che...
Chrono-chemotherapy combined with IMRT in locoregionally advanced nasopharyngeal carcinoma: A prospective randomized study.
6113 Background: Induction chemotherapy followed by radiotherapy with concurrent cisplatin is a standard treatment for loc...
Comparative mortality burden of primary brain malignancies versus brain metastases in the United States.
e14011 Background: Primary brain malignancies and brain metastases represent major contributors to neurological morbidity...
Trends in melanoma mortality among U.S. adults aged ≥55 before and after the introduction of immunotherapy: A CDC WONDER Joinpoint-style analysis.
e21579 Background: Immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced melanoma and produced du...
Relationships between clinical stage, pathological stage, and disease-free (DFS) survival in renal cell carcinoma as used to inform future neoadjuvant study design: ECOG-ACRIN EA8143 PROSPER analysis.
4540 Background: Estimating risk of renal cell cancer (RCC) relapse based only on pre-surgical data is key to future neoad...
Occult neoplasia in risk-reducing bilateral salpingo-oophorectomy: Pathological findings and clinical implications.
e22558 Background: RRSO is a well-established risk-reducing strategy for ovarian and fallopian tube cancer in genetically...
Allostatic load, neutrophil-to-lymphocyte ratio, and body composition in patients with metastatic prostate cancer.
e17135 Background: Allostatic load (AL), a composite biomarker index of multisystem physiologic dysregulation, and neutrop...
HistoChrome: Virtual multiplex immunohistochemistry from routine H&E in colorectal cancer.
3523 Background: In colorectal cancer (CRC), immunohistochemistry (IHC) is central to assessment of spatial protein expres...
Clinicogenomic profile and progression patterns in lung squamous cell carcinoma treated with immune checkpoint inhibitors.
e20593 Background: Lung squamous cell carcinoma (LUSC) is associated with inferior outcomes to immune-checkpoint inhibitor...
Commercial price variation in precision oncology testing across US hospitals.
11062 Background: Precision oncology testing using clinically validated biomarker tests is standard of care for solid tumo...
Cytokine dynamics in a phase II trial of metronomic carboplatin/paclitaxel combined with cemiplimab in recurrent/metastatic head and neck squamous cell carcinoma.
6044 Background: Standard-dose chemotherapy combined with immunotherapy improves response rates in recurrent or metastatic...